{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:30:09Z","timestamp":1791232209003,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) is associated with poor prognosis and limited efficacy of current first-line therapies. Combining locoregional and systemic therapies may enhance antitumor immunity. However, the safety and efficacy of dual locoregional therapy (LRT) with stereotactic body radiotherapy (SBRT) and transarterial embolization (TAE) along with targeted immunotherapy is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective real-world study, we analyzed 204 patients with Barcelona Clinic Liver Cancer stage C HCC and PVTT treated with SBRT plus lenvatinib and sintilimab, with or without TAE, between June 2018 and December 2022. Propensity score matching (PSM) was performed to balance baseline characteristics. The primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoints included local control (LC) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM (64 patients per group), the TAE group showed significantly longer median PFS (11.0 vs. 6.0 months; HR\u00a0=\u00a00.71, p=0.044) and a trend toward improved LC than the non-TAE group (51.0 vs. 36.0 months; HR\u00a0=\u00a00.54, p=0.066), but comparable OS (19.0 vs. 18.0 months; p=0.606). Multivariate analysis confirmed TAE as an independent predictor of reduced risk of progression (HR\u00a0=\u00a00.52, 95% CI: 0.36\u20130.76). Objective response rates (40.6% vs. 39.1%, p=0.861) and grade \u22653 treatment-related adverse events (50.0% vs. 50.0%, p=0.854) were similar between groups. TAE did not increase hematologic or hepatic toxicity, supporting its tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Adding TAE to SBRT, lenvatinib, and sintilimab prolonged the median PFS in patients with advanced HCC and PVTT, showing comparable safety. This real-world study supports dual LRT combined with targeted immunotherapy as a feasible treatment option and merits prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1644027","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:03:41Z","timestamp":1772607821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Jun","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Senior Department of Oncology, Chinese PLA General Hospital, Chinese PLA Medical School","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Senior Department of Oncology, Chinese PLA General Hospital, Chinese PLA Medical School","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Senior Department of Oncology, Chinese PLA General Hospital, Chinese PLA Medical School","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition & Health Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taifeng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhang","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Senior Department of Oncology, Chinese PLA General Hospital, Chinese PLA Medical School","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1666805","article-title":"Hepatocellular carcinoma with portal vein tumor involvement: best management strategies","volume":"38","author":"Liu","year":"2018","journal-title":"Semin liver disease"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29006","article-title":"Aldehyde dehydrogenase-2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice","volume":"65","author":"Hou","year":"2017","journal-title":"Hepatol (Baltimore Md)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"tzaf002","DOI":"10.1093\/bjro\/tzaf002","article-title":"Outcomes with radiotherapy in multimodality treatment for hepatocellular carcinoma with portal vein tumour thrombosis","volume":"7","author":"Sahai","year":"2025","journal-title":"BJR Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1254158","article-title":"Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41467-020-20243-8","article-title":"Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress","volume":"12","author":"Huang","year":"2021","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2019.01.027","article-title":"Combined locoregional-immunotherapy for liver cancer","volume":"70","author":"Greten","year":"2019","journal-title":"J hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00546-2","article-title":"Therapeutic targeting of tumour myeloid cells","volume":"23","author":"Barry","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e010534","DOI":"10.1136\/jitc-2024-010534","article-title":"Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.023","article-title":"Role of locoregional therapies in the wake of systemic therapy","volume":"72","author":"Palmer","year":"2020","journal-title":"J hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1186\/s12885-016-2894-9","article-title":"Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm","volume":"16","author":"Su","year":"2016","journal-title":"BMC cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0268779","DOI":"10.1371\/journal.pone.0268779","article-title":"Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis","volume":"17","author":"Zhang","year":"2022","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/TCRM.S126181","article-title":"Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis","volume":"13","author":"Zhao","year":"2017","journal-title":"Ther Clin Risk management"},{"key":"B16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00535-009-0033-y","article-title":"Intra-arterial 5-fluorouracil\/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis","volume":"44","author":"Katamura","year":"2009","journal-title":"J gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med physics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.02.013","article-title":"Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma","volume":"19","author":"Maluccio","year":"2008","journal-title":"J Vasc interventional radiology: JVIR"},{"key":"B19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J hepatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002064","article-title":"The tumor burden score: A new \"Metro-ticket\" Prognostic tool for colorectal liver metastases based on tumor size and number of tumors","volume":"267","author":"Sasaki","year":"2018","journal-title":"Ann surgery"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-018-3688-y","article-title":"Utility of tumor burden score to stratify prognosis of patients with hepatocellular cancer: results of 4759 cases from ITA.LI.CA study group","volume":"22","author":"Vitale","year":"2018","journal-title":"J gastrointestinal surgery: Off J Soc Surg Alimentary Tract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)00418-K","article-title":"Hepatic toxicity resulting from cancer treatment","volume":"31","author":"Lawrence","year":"1995","journal-title":"Int J Radiat oncology biology physics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.10.014","article-title":"Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh Grade A cirrhosis","volume":"98","author":"Liang","year":"2011","journal-title":"Radiotherapy Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2592","article-title":"Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus","volume":"29","author":"Yue","year":"2023","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-024-03813-x","article-title":"Transarterial embolization enhances programmed cell death ligand 1 expression and influences CD8(+)T lymphocytes cytotoxicity in an orthotopic hepatocellular carcinoma rat model","volume":"47","author":"Zhang","year":"2024","journal-title":"Cardiovasc interventional radiology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1348679","article-title":"Clinical application of spectral CT perfusion scanning in evaluating the blood supply source of portal vein tumor thrombus in hepatocellular carcinoma","volume":"13","author":"Pan","year":"2023","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_2351_24","article-title":"Clinical outcomes with combination of stereotactic body radiation therapy in patients with hepatocellular carcinoma","volume":"21","author":"Sahai","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000004390","article-title":"125I stent plus combination therapy for HCC and portal vein tumor thrombosis: a nationwide target trial emulation","author":"Mei","year":"2025","journal-title":"Int J Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01205","article-title":"Long-term survival analysis of transarterial chemoembolization plus radiotherapy vs. Radiotherapy for hepatocellular carcinoma with macroscopic vascular invasion","volume":"10","author":"Su","year":"2020","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000001100","article-title":"Local ablation therapy for hepatocellular carcinoma: clinical significance of tumor size, location, and biology","volume":"60","author":"Lee","year":"2025","journal-title":"Invest Radiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29110692","article-title":"Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360)","volume":"29","author":"Tiziana","year":"2022","journal-title":"Curr Oncol (Toronto Ont)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1644027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:03:42Z","timestamp":1772607822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1644027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1644027"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1644027","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1644027"}}